Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TL011 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TL011 | EXPERIMENTAL | - |
| MabThera® | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TL011 | BIOLOGICAL | 375 mg/m2 iv every 3 weeks for 8 cycles |
| Rituximab | BIOLOGICAL | 375 mg/m2 iv every 3 weeks for 8 cycles |
Inclusion Criteria: * Newly diagnosed subjects with a confirmed pathologic diagnosis of diffuse large B cell non-Hodgkin's lymphoma (DLBCL) based on the 2008 World Health Organization classification. 2.CD20+ lymphoma cells at screening * 18-80 (inclusive) years of age at screening * Ann Arbor St...
TL011 is an investigational monoclonal antibody being studied for the treatment of diffuse large B-cell lymphoma (DLBCL), a type of non-Hodgkin's lymphoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
TL011 targets CD20, a protein found on the surface of B-cells. The clinical trial for TL011 specifically enrolled subjects with CD20-positive diffuse B-cell non-Hodgkin's lymphoma, indicating that the drug is designed to bind to this antigen on malignant B-cells.
TL011 is being developed by Teva Pharmaceutical Industries Limited, a company listed on the stock exchange under the ticker symbol TEVA. The company is conducting clinical research to evaluate the safety and efficacy of this investigational monoclonal antibody.
TL011 is in Phase 1 clinical development. The drug is investigational and has not yet received approval from regulatory agencies. It is being studied in a completed Phase 1 trial that enrolled 186 participants with DLBCL.
TL011 has one completed clinical trial registered under NCT01205737. This was a double-blind, randomized, active-controlled Phase 1 study in subjects with CD20-positive diffuse B-cell non-Hodgkin's lymphoma, conducted across multiple countries including Bulgaria, France, Hungary, Italy, and Russia.
TL011 is not the same as rituximab, though both are monoclonal antibodies targeting CD20. The clinical trial for TL011 used an active control, meaning it was compared against an existing treatment, but the specific comparator is not identified in the available information.